Key Points
- Insider sale: Corcept Therapeutics insider Sean Maduck sold 75,000 shares on May 27 at an average price of $65.59, totaling about $4.92 million. After the transaction, he retained 8,977 shares, cutting his ownership by 89.31%.
- Stock and earnings backdrop: CORT shares were up 1.6% and opened at $69.49, near the upper end of its 52-week range of $28.66 to $91.00. The company recently reported a quarterly EPS loss of $0.30, missing estimates, while revenue of $164.9 million also came in below consensus.
- Analyst and pipeline sentiment: Despite the insider sale, analysts have turned more bullish, with Canaccord Genuity and HC Wainwright raising price targets and reiterating buy ratings. Investor optimism is also tied to Corcept’s plan to resubmit the NDA for relacorilant in Cushing’s syndrome, a key pipeline catalyst.
Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) insider Joseph Douglas Lyon sold 5,000 shares of the firm's stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $65.00, for a total value of $325,000.00. Following the transaction, the insider owned 6,230 shares of the company's stock, valued at $404,950. This trade represents a 44.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Corcept Therapeutics Price Performance
Shares of CORT opened at $69.49 on Friday. Corcept Therapeutics Incorporated has a 1 year low of $28.66 and a 1 year high of $91.00. The company has a market capitalization of $7.46 billion, a price-to-earnings ratio of 198.55 and a beta of 0.36. The business has a 50-day moving average of $48.02 and a 200-day moving average of $52.30.
Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.19). Corcept Therapeutics had a return on equity of 7.40% and a net margin of 6.14%.The company had revenue of $164.90 million for the quarter, compared to the consensus estimate of $185.83 million. During the same quarter last year, the business earned $0.17 earnings per share. Corcept Therapeutics's revenue was up 4.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Corcept Therapeutics Incorporated will post 0.53 EPS for the current year.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on CORT. Piper Sandler raised their price objective on Corcept Therapeutics from $73.00 to $88.00 and gave the stock an "overweight" rating in a research report on Friday, May 1st. HC Wainwright raised their price objective on Corcept Therapeutics from $75.00 to $95.00 and gave the stock a "buy" rating in a research report on Thursday. UBS Group set a $135.00 price objective on Corcept Therapeutics in a research report on Thursday. Zacks Research upgraded Corcept Therapeutics from a "strong sell" rating to a "hold" rating in a report on Monday, May 4th. Finally, Wolfe Research upgraded Corcept Therapeutics from an "underperform" rating to a "peer perform" rating in a report on Thursday, March 26th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $88.83.
View Our Latest Stock Analysis on Corcept Therapeutics
Key Corcept Therapeutics News
Here are the key news stories impacting Corcept Therapeutics this week:
- Positive Sentiment: Canaccord Genuity raised its price target on Corcept Therapeutics to $135 from $110 and reiterated a buy rating, signaling greater confidence in upside potential. Canaccord Genuity price target update
- Positive Sentiment: HC Wainwright lifted its 2026 earnings estimates for CORT, including higher Q3, Q4, and full-year EPS forecasts, while maintaining a buy rating and $95 target. Higher profit expectations often support the stock. HC Wainwright estimate revisions
- Positive Sentiment: Corcept said it plans to resubmit the NDA for relacorilant in Cushing’s syndrome, which keeps a key pipeline asset alive and appears to be the main business-specific catalyst behind the recent rally. Relacorilant NDA resubmission article
- Neutral Sentiment: Stockholders approved an expanded incentive plan and board-related matters at the 2026 annual meeting; this is supportive of governance but not a major immediate earnings driver. Stockholders approve expanded incentive plan and board
Institutional Investors Weigh In On Corcept Therapeutics
A number of hedge funds have recently added to or reduced their stakes in CORT. Royal Bank of Canada increased its holdings in Corcept Therapeutics by 18.9% in the first quarter. Royal Bank of Canada now owns 15,385 shares of the biotechnology company's stock worth $1,757,000 after purchasing an additional 2,444 shares in the last quarter. Amundi bought a new stake in Corcept Therapeutics in the first quarter worth approximately $450,000. NewEdge Advisors LLC bought a new stake in Corcept Therapeutics in the first quarter worth approximately $518,000. EverSource Wealth Advisors LLC increased its holdings in Corcept Therapeutics by 273.3% in the second quarter. EverSource Wealth Advisors LLC now owns 1,441 shares of the biotechnology company's stock worth $106,000 after purchasing an additional 1,055 shares in the last quarter. Finally, Marshall Wace LLP increased its holdings in Corcept Therapeutics by 795.3% in the second quarter. Marshall Wace LLP now owns 46,200 shares of the biotechnology company's stock worth $3,391,000 after purchasing an additional 41,040 shares in the last quarter. 93.61% of the stock is currently owned by institutional investors.
About Corcept Therapeutics
(
Get Free Report)
Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.
The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
